logo

Karyopharm Therapeutics Inc. (KPTI)



Trade KPTI now with
  Date
  Headline
5/12/2022 11:02:43 AM Karyopharm Announces XPOVIO Data To Be Presented
5/5/2022 7:09:52 AM Karyopharm Q1 Loss/shr Narrows To $0.53 From $0.77 Last Year
3/16/2022 7:04:58 AM Karyopharm To Present Phase 3 SIENDO Study Of Selinexor In Advanced Or Recurrent Endometrial Cancer At ESMO
3/14/2022 7:10:49 AM Karyopharm Therapeutics Appoints Elhan Webb As SVP Of Investor Relations
2/22/2022 7:18:01 AM Karyopharm Names Patricia Judson As SVPof Medical Strategy
2/8/2022 7:37:31 AM Karyopharm Q4 Net Product Revenue $29.8 Mln, Up 47% From Prior Year
2/8/2022 7:34:12 AM Karyopharm : Phase 3 Study Of Selinexor Meets Primary Endpoint In Advanced Or Recurrent Endometrial Cancer
1/24/2022 7:11:22 AM Karyopharm Receives Orphan Drug Designation From FDA For Eltanexor For Treatment Of Myelodysplastic Syndromes
1/10/2022 7:12:38 AM Karyopharm Expects Net Product Revenues Of XPOVIO To Be About $29.7 Mln For Q4